Tool for functional genomics. Nucleic Acids Res. 2012;40(Web Server issue):W478?3. 80. Jacob A, Matiello M, Wingerchuk DM, Lucchinetti CF, Pittock SJ, Weinshenker BG. Neuromyelitis optica: changing concepts. J Neuroimmunol. 2007;187(1?):126?8. 81. Kim W, Kim SH, Kim HJ. New insights into neuromyelitis optica. J Clin Neurol. 2011;7(3):115?7. 82. Bergamaschi R, Tonietti S, Franciotta D, Candeloro E, Tavazzi E, Piccolo G, Romani A, Cosi V. Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Staurosporine Mult Scler. 2004;10(1):2?. 83. Mata S, Lolli F. Neuromyelitis optica: an update. J Neurol Sci. 2011;303(1?):13?1. 84. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53(5):1107?4. 85. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106?2. 86. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485?. 87. Etemadifar M, Nasr Z, Khalili B, Taherioun M, Vosoughi R. Epidemiology of neuromyelitis optica in the world: a systematic review and metaanalysis. Mult Scler Int. 2015;2015:174720. 88. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176?0. 89. Rivera JF, Kurtzke JF, Booth VJ. Corona VTt: Characteristics of Devic's disease (neuromyelitis optica) in Mexico. J Neurol. 2008;255(5):710?.Sengupta et al. Clin Proteom (2016) 13:Page PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/6833145 9 of90. Lana-Peixoto MA. Devic's neuromyelitis optica: a critical review. Arq Neuropsiquiatr. 2008;66(1):120?8. 91. Wingerchuk DM. Neuromyelitis optica: effect of gender. J Neurol Sci. 2009;286(1?):18?3. 92. Cossburn M, Tackley G, Baker K, Ingram G, Burtonwood M, Malik G, Pickersgill T, te Water Naude J, Robertson N. The prevalence of neuromyelitis optica in South East Wales. Eur J Neurol. 2012;19(4):655?. 93. Banwell B, Tenembaum S, Lennon VA, Ursell E, Kennedy J, Bar-Or A, Weinshenker BG, Lucchinetti CF, Pittock SJ. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology. 2008;70(5):344?2. 94. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology. 2003;60(5):848?3. 95. Staugaitis SM, Roberts JK, Sacco RL, Miller JR, Dwork AJ. Devic type multiple sclerosis in an 81 year old woman. J Neurol Neurosurg Psychiatry. 1998;64(3):417?. 96. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol. 2005;7(3):173?2. 97. Singh V, Hintzen RQ, Luider TM, Stoop MP. Proteomics technologies for biomarker discovery in multiple sclerosis. J Neuroimmunol. 2012;248(1?):40?. 98. Yuan X, Desiderio DM. Proteomics analysis of human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;815(1?):179?9. 99. Khwaja FW, Nolen JD, Mendrinos SE, Lewis MM, Olson JJ, Pohl J, Van Meir EG, Ritchie JC, Brat DJ. Proteomic analysis of cerebrospinal fluid100. 101. 102. 103.104. 105.discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics. 2006;6(23):6277?7. Jiang S, Wu J, Yang Y, Liu J, Ding Y, Ding M. Proteomic analysis of the.